Loading...
Please wait, while we are loading the content...
Similar Documents
Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia
| Content Provider | Scilit |
|---|---|
| Author | Kinjyo, Ichiko Matlawska-Wasowska, Ksenia Chen, Xiaoru Monks, Noel R. Burke, Patricia Winter, Stuart S. Wilson, Bridget S. |
| Copyright Year | 2017 |
| Description | Journal: Pediatric Blood & Cancer Moxetumomab pasudotox is a second-generation recombinant immunotoxin against CD22 on B-cell lineages. Antileukemic activity has been demonstrated in children with chemotherapy-refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), with variable responses. Here, we report in vitro and in vivo evaluation of moxetumomab pasudotox treatment of human cell lines and patient-derived cells as a preliminary study to understand characteristics of sensitivity to treatment. Binding, internalization, and apoptosis were evaluated using fluorescently tagged moxetumomab pasudotox. Studies in NOD-scid IL2Rgnull mice showed a modest survival benefit in mice engrafted with 697 cells but not in NALM6 or the two patient-derived xenograft models. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501879/pdf |
| e-ISSN | 15455017 |
| DOI | 10.1002/pbc.26604 |
| Journal | Pediatric Blood & Cancer |
| Issue Number | 11 |
| Volume Number | 64 |
| Language | English |
| Publisher | Wiley-Blackwell |
| Publisher Date | 2017-04-27 |
| Access Restriction | Open |
| Subject Keyword | Journal: Pediatric Blood & Cancer Acute Lymphoblastic Leukemia |
| Content Type | Text |
| Resource Type | Article |